What is Cell Source Inc's earnings per share (EPS)?

Cell Source Inc (CLCS) reported diluted earnings per share of $-0.14 for fiscal year 2024. This represents a 17.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Cell Source Inc Financials

CLCS

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2025 Currency USD FYE December

This page shows Cell Source Inc (CLCS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CLCS FY2024 2026-05-14

Tiny asset levels and a deepening equity deficit show a business being kept alive by financing structure, not operating scale.

From FY2023 to FY2024, per-share losses narrowed from 0.17 to 0.14 even as shares outstanding rose to 45.0M and retained losses deepened to $46.2M; that combination suggests the apparent EPS improvement came partly from dilution math rather than a repaired balance sheet. At the same time, cash increased to only $75K while liabilities reached $18.8M, so the capital structure stayed far heavier than the operating asset base.

The most stable pattern across the last three valid years is balance-sheet erosion: liabilities climbed from $13.0M in FY2022 to $18.8M in FY2024 while total assets remained below $500K. That means this is less a revenue-funded enterprise than a company whose survival depends on how obligations are carried and how new shares are issued.

Some figures from recent filings were inconsistent and were omitted from this summary.

Financial Health Signals

Financial health score pending refresh

We are recalculating Cell Source Inc's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

$-0.14

YoY+17.6%

Cell Source Inc earned $-0.14 per diluted share (EPS) in fiscal year 2024. This represents an increase of 17.6% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$75K

YoY+236.1%

5Y CAGR+21.7%

10Y CAGR+14.4%

Cell Source Inc held $75K in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

45M

YoY+13.1%

5Y CAGR+10.7%

10Y CAGR+6.7%

Cell Source Inc had 45M shares outstanding in fiscal year 2024. This represents an increase of 13.1% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

CLCS Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	$1.9M+52.2%	$1.3M+52.5%	$835K	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	$629K+37.6%	$457K+99.9%	$229K
Income Tax	N/A	N/A	N/A	N/A	$0	$0
Net Income	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	$-0.14+17.6%	$-0.17+5.6%	$-0.18+5.3%	$-0.19	N/A	N/A

Metric	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$483K	N/A	$471K+26.0%	$374K	N/A	N/A	$481K-10.9%	$540K
Operating Income	-$999K	N/A	-$832K+30.3%	-$1.2M	N/A	N/A	-$995K-9.9%	-$905K
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	-$1.5M	N/A	N/A	N/A	-$1.2M
EPS (Diluted)	$-0.04	N/A	$-0.040.0%	$-0.040.0%	$-0.04	N/A	$-0.040.0%	$-0.04

CLCS Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$287K+46.8%	$195K-52.4%	$410K+30.6%	$314K-30.6%	$452K+294.1%	$115K
Current Assets	N/A	N/A	N/A	$314K-30.1%	$449K	N/A
Cash & Equivalents	$75K+236.1%	$22K-90.0%	$223K+139.2%	$93K-61.5%	$242K+765.8%	$28K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$18.8M+19.1%	$15.8M+21.2%	$13.0M+28.6%	$10.1M+20.7%	$8.4M+43.4%	$5.9M
Current Liabilities	N/A	N/A	N/A	$10.1M+20.7%	$8.4M+47.1%	$5.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$18.5M-18.7%	-$15.6M-23.6%	-$12.6M-28.6%	-$9.8M-23.6%	-$7.9M-38.4%	-$5.7M
Retained Earnings	-$46.2M-10.8%	-$41.7M-14.6%	-$36.3M-16.6%	-$31.2M-21.3%	-$25.7M-21.6%	-$21.1M

Metric	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23
Total Assets	$292K+2.1%	$287K+8.3%	$265K-38.4%	$430K+420.4%	$83K-57.7%	$195K-21.4%	$248K-31.5%	$362K
Current Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cash & Equivalents	$1K-98.3%	$75K+224.6%	$23K-74.6%	$91K+393591.3%	$23-99.9%	$22K+759.9%	$3K-88.3%	$22K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$20.4M+8.5%	$18.8M-2.0%	$19.2M+8.2%	$17.7M+5.4%	$16.8M+6.5%	$15.8M-2.9%	$16.3M+6.3%	$15.3M
Current Liabilities	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$20.1M-8.6%	-$18.5M+2.1%	-$18.9M-9.4%	-$17.3M-3.4%	-$16.8M-7.3%	-$15.6M+2.6%	-$16.0M-7.3%	-$14.9M
Retained Earnings	-$47.7M-3.2%	-$46.2M-0.7%	-$45.8M-3.2%	-$44.4M-3.5%	-$42.9M-3.1%	-$41.7M-2.6%	-$40.6M-3.4%	-$39.3M

CLCS Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	N/A
Current Ratio	N/A	N/A	N/A	0.03-0.0	0.05	N/A
Debt-to-Equity	N/A	N/A	N/A	N/A	N/A	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	-346.4%	N/A	N/A	N/A	-342.7%
Current Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Debt-to-Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$18.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Oncotelic Therapeutics Inc OTLC

$17.7M

Finch Therapeutics Group, Inc. FNCH

$5.0M

Biomind Labs Inc BMNDF

$3.9M

ACCUSTEM SCIENCES INC ACUT

$3.1M

Pharmather Holdings Ltd PHRRF

$3.2M

Frequently Asked Questions

What are Cell Source Inc's total assets?

Cell Source Inc (CLCS) had $287K in total assets as of fiscal year 2024, including both current and long-term assets.

How many shares does Cell Source Inc have outstanding?

Cell Source Inc (CLCS) had 45M shares outstanding as of fiscal year 2024.

Why is Cell Source Inc's debt-to-equity ratio negative or not reported?

Cell Source Inc (CLCS) has negative shareholder equity of -$18.5M as of fiscal year 2024, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.